The effects of PPARγ agonist rosiglitazone on neointimal hyperplasia in rabbit carotid anastomosis model

The effects of PPARγ agonist rosiglitazone on neointimal hyperplasia in rabbit carotid anastomosis model

<p>Abstract</p> <p>Background</p> <p>Neointimal hyperplasia involving smooth muscle cell (SMC) proliferation, migration and extracellular matrix (ECM) degradation is an important component of atherosclerosis. It develops as a response to vascular injury after balloon an...

Full description

Bibliographic Details
Main Authors:	Guzeloglu Mehmet, Reel Buket, Atmaca Soner, Bagrıyanık Alper, Hazan Eyup
Format:	Article
Language:	English
Published:	BMC 2012-06-01
Series:	Journal of Cardiothoracic Surgery
Subjects:	Neointima Rosiglitazone Matrix metalloproteinases (MMPs) Rabbit
Online Access:	http://www.cardiothoracicsurgery.org/content/7/1/57

Similar Items

Neointimal hyperplasia after carotid transection and anastomosis surgery is associated with degradation of decorin and platelet-derived growth factor signaling
by: Roshan J. D'Cruz, MD, et al.
Published: (2021-01-01)

Rosiglitazona e lesão vascular em coelhos hipercolesterolêmicos: avaliação da formação neointimal Rosiglitazona y lesión vascular en conejos hipercolesterolémicos Rosiglitazone and vascular injury in hypercholesterolemic rabbits: neointimal formation assessment
by: Alexandre Alessi, et al.
Published: (2010-09-01)

Daily Intraperitoneal Administration of Rosiglitazone Does Not Improve Lung Function or Alveolarization in Preterm Rabbits Exposed to Hyperoxia
by: Giorgio Aquila, et al.
Published: (2022-07-01)

Macrophage PPARγ inhibits Gpr132 to mediate the anti-tumor effects of rosiglitazone
by: Wing Yin Cheng, et al.
Published: (2016-10-01)

Perivascular mast cells regulate vein graft neointimal formation and remodeling
by: Junxi Wu, et al.
Published: (2015-08-01)

Regularities of plaque stabilization in various scenarios of neointimal calcification and vascularization
by: N. Yu. Osyaev, et al.
Published: (2021-07-01)

Neointimal formation in two apolipoprotein E-deficient mouse strains with different atherosclerosis susceptibility
by: Weibin Shi, et al.
Published: (2004-11-01)

Metformin attenuates carotid neointimal hyperplasia by modulating the vascular smooth muscle cell phenotype transformation through upregulation of TET2, Nur77 and calponin
by: Lin Hao, et al.
Published: (2021-01-01)

Effect of Rosiglitazone on Coronary Angiogenesis in Diabetic and Control Rats
by: Ensieh Salehi, et al.
Published: (2011-06-01)

Effect of hyperglycemia and rosiglitazone on renal and urinary neprilysin in db/db diabetic mice
by: Laale F. Alawi, et al.
Published: (2020-02-01)

Rosiglitazone suppresses RANKL‐induced NFATc1 autoamplification by disrupting the physical interaction between NFATc1 and PPARγ
by: Kyeong‐Lok Park, et al.
Published: (2018-10-01)

The lysine methyltransferase SMYD2 facilitates neointimal hyperplasia by regulating the HDAC3–SRF axis
by: Xiaoxuan Zhong, et al.
Published: (2024-02-01)

Expression of p-PPARγ in the aging thoracic aorta of spontaneously hypertensive rat and inhibitory effect of rosiglitazone
by: Hai-Feng Yuan, et al.
Published: (2014-12-01)

Spotlight on the Low dose Rosiglitazone/ Metformin Combination In Prevention of Type 2 Diabetes
by: Muhammad Abdul Hadi
Published: (2010-10-01)

The impact of acute rosiglitazone on insulin pharmacokinetics at the blood‐brain barrier
by: Demi C. Galindo, et al.
Published: (2020-07-01)

Possible modulation of the antidiabetic effect of rosiglitazone by buspirone
by: Wafaa R. Mohamed, et al.
Published: (2012-06-01)

Rosiglitazone regulates astrocyte polarization and neuroinflammation in a PPAR-γ dependent manner after experimental traumatic brain injury
by: Xu Ren, et al.
Published: (2024-04-01)

The PPARγ Agonist Rosiglitazone Suppresses Syngeneic Mouse SCC (Squamous Cell Carcinoma) Tumor Growth through an Immune-Mediated Mechanism
by: Raymond L. Konger, et al.
Published: (2019-06-01)

Rosiglitazone ameliorates palmitic acid-induced cytotoxicity in TM4 Sertoli cells
by: Xie Ge, et al.
Published: (2018-10-01)

Budget impact of rosiglitazone in type 2 diabetes
by: Orietta Zaniolo, et al.
Published: (2007-03-01)

MMP-9 Deletion Attenuates Arteriovenous Fistula Neointima through Reduced Perioperative Vascular Inflammation
by: Yu-Chung Shih, et al.
Published: (2021-05-01)

Rosiglitazone attenuates hypoxia-induced renal cell apoptosis by inhibiting NF-κB signaling pathway in a PPARγ-dependent manner
by: Jun-Yu Wei, et al.
Published: (2022-12-01)

MIA SH3 Domain ER Export Factor 3 Deficiency Prevents Neointimal Formation by Restoring BAT-Like PVAT and Decreasing VSMC Proliferation and Migration
by: Yu Lei, et al.
Published: (2021-11-01)

Neointimal dissection – a rare complication to endovascular treatment in grafts and stent grafts
by: Anne Sofie F. Larsen, et al.
Published: (2023-10-01)

Streptozotocin-induced vascular and biochemical changes in rats: Effects of rosiglitazone vs. metformin
by: Dalia O. Saleh, et al.
Published: (2013-12-01)

A Preliminary Study of the Therapeutic Role of Human Early Fetal Aorta-derived Endothelial Progenitor Cells in Inhibiting Carotid Artery Neointimal Hyperplasia
by: Rong-Wei Xu, et al.
Published: (2015-01-01)

Expression of Matrix Metalloproteinases (MMPs) and Their Tissue Inhibitors (TIMPs) in Frozen Sperm of Rabbit
by: Sang Hwan Kim, et al.
Published: (2019-09-01)

Bioinformatics analysis reveals the potential target of rosiglitazone as an antiangiogenic agent for breast cancer therapy
by: Adam Hermawan, et al.
Published: (2022-09-01)

Rosiglitazone Protects Endothelial Cells From Irradiation-Induced Mitochondrial Dysfunction
by: Bjorn Baselet, et al.
Published: (2020-03-01)

A novel translabial platform utilizing bioexcipients from Litchi chinesis for the delivery of rosiglitazone maleate
by: N.V. Satheesh Madhav, et al.
Published: (2013-12-01)

European Medicines Agency (EMA) announces termination of Avandia (rosiglitazone usage in Europe)
by: Inna Igorevna Klefortova
Published: (2010-09-01)

Rosiglitazone Ameliorates Cardiac and Skeletal Muscle Dysfunction by Correction of Energetics in Huntington’s Disease
by: Marta Tomczyk, et al.
Published: (2022-08-01)

Rosiglitazone increases endothelial cell migration and vascular permeability through Akt phosphorylation
by: Yun Hyi Ku, et al.
Published: (2017-08-01)

Adjunctive rosiglitazone treatment for severe pediatric malaria: A randomized placebo-controlled trial in Mozambican children
by: Rosauro Varo, et al.
Published: (2024-02-01)

GDF11 alleviates neointimal hyperplasia in a rat model of artery injury by regulating endothelial NLRP3 inflammasome activation and rapid re-endothelialization
by: Lei Li, et al.
Published: (2022-01-01)

Metalloproteinases and Their Inhibitors: Potential for the Development of New Therapeutics
by: Maryam Raeeszadeh-Sarmazdeh, et al.
Published: (2020-05-01)

The serum levels of circulating matrix metalloproteinase MMP-9, MMP-2/TIMP-2 complex and TIMP-1 do not change significantly during normal pregnancy: a pilot study
by: Ritva Nissi, et al.
Published: (2021-01-01)

The Effects of Rosiglitazone on Task Specific Anxiety-Like Behavior and Novelty Seeking in a Model of Chronic Adolescent Unpredictable Stress
by: Hannah G. Sexton, et al.
Published: (2022-02-01)

Development and validation of a repharsed phase- HPLC method for simultaneous determination of rosiglitazone and glimepiride in combined dosage forms and human plasma
by: El-Enany Nahed M, et al.
Published: (2012-01-01)

Rosiglitazone Inhibits HMC-1 Cell Migration and Adhesion through a Peroxisome Proliferator-Activated Receptor Gamma-Dependent Mechanism
by: Guqin Zhang, et al.
Published: (2014-02-01)